Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 3.17 AUD -1.25% Market Closed
Market Cap: 257.6m AUD

Wall Street
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 6.22 AUD with a low forecast of 6.16 AUD and a high forecast of 6.41 AUD.

Lowest
Price Target
6.16 AUD
94% Upside
Average
Price Target
6.22 AUD
96% Upside
Highest
Price Target
6.41 AUD
102% Upside
Mayne Pharma Group Ltd Competitors:
Price Targets
SUPRIYA
Supriya Lifescience Ltd
19% Upside
CLN
Celon Pharma SA
31% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
14% Upside
600867
Tonghua Dongbao Pharmaceutical Co Ltd
35% Upside
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
34% Upside
NOVN
Novartis AG
2% Upside
GS71
GSK plc
0% Upside
ORX
Orexo AB
35% Upside

Revenue
Forecast

Revenue Estimate
Mayne Pharma Group Ltd

For the last 7 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -4%. The projected CAGR for the next 2 years is 13%.

-4%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MYX's stock price target?
Price Target
6.22 AUD

According to Wall Street analysts, the average 1-year price target for MYX is 6.22 AUD with a low forecast of 6.16 AUD and a high forecast of 6.41 AUD.

What is Mayne Pharma Group Ltd's Revenue forecast?
Projected CAGR
13%

For the last 7 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -4%. The projected CAGR for the next 2 years is 13%.

Back to Top